Infrequent mutations and no methylation of CDKN2A (p16/MTS1) and CDKN2B (p15/MTS2) in hepatocellular carcinoma in Taiwan

European Journal of Cancer

Volumn 34, Issue 11, 1998, Pages 1789-1795

  Lin, Y W ^a   Chen, C H ^b   Huang, G T ^b   Lee, P H ^b   Wang, J T ^b   Chen, D S ^b   Lu, F J ^a   Sheu, J C ^b  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

CDKN2 p16 MTS1; Deletion; Hepatocellular carcinoma; Methylation; P15 MTS2

Indexed keywords

CYCLIN D1; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; GENE PRODUCT; PROTEIN P15; PROTEIN P16; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CHROMOSOME 9P; CLINICAL ARTICLE; CONTROLLED STUDY; CPG ISLAND; FEMALE; GENE MUTATION; HETEROZYGOSITY LOSS; HOMOZYGOSITY; HUMAN; HUMAN TISSUE; LIVER CELL CARCINOMA; MALE; METHYLATION; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; TAIWAN; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BLOTTING, SOUTHERN; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CELL CYCLE PROTEINS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; DNA METHYLATION; FEMALE; GENE DELETION; HOMOZYGOTE; HUMANS; LIVER NEOPLASMS; LOSS OF HETEROZYGOSITY; MALE; MIDDLE AGED; MUTATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 0032189238     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(98)00189-0     Document Type: Article

References (31)

1. 1. Linsell DA, Higginson J. The geographic pathology of liver cell cancer. In Cameron HM, Linsell DA, Warwick GP, eds. Liver Cell Cancer. New York, Elsevier Science, 1976, 1-16.
2. 2. Beasley RP. Hepatitis B virus as the etiologic agent in hepatocellular carcinoma - epidemiologic considerations. Hepatology 1982, 2, 21-26.
3. 3. Chen DS. Hepatitis B virus infections, its sequelae, and prevention in Taiwan. In Okuda K, Ishak KG, eds. Neoplasm of the Liver. Tokyo, Springer, 1987, 71-80.
4. 4. Sheu JC, Huang GT, Shih LN, et al. Hepatitis C and B viruses in hepatitis B surface antigen negative hepatocellular carcinoma. Gastroenterology 1992, 103, 1322-1327.
5. 5. Sheu JC, Huang GT, Lee PH, et al. Mutation of p53 gene in hepatocellular carcinoma in Taiwan. Cancer Res 1992, 52, 6098-6100.
6. 6. Cannon A, et al. Assignment of a locus for familial melanoma, MLM, to chromosome 9p13-p22. Science 1992, 258, 1148-1152.
7. 7. Diaz MO, Rubin CM, Harden A, et al. Deletions of interferon genes in acute lymphoblastic leukemia. N Engl J Med 1990, 332, 77-82.
8. 8. Cheng JQ, Jhanwar SC, Lu YY, Testa JR. Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. Cancer Res 1993, 53, 4761-4763.
9. 9. Fountain JW, Karayiorgou M, et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc Natl Acad Sci USA 1992, 89, 10557-10561.
10. 10. Oplopade OI, Buchhagen DL, Malik K, et al. Homozygous loss of the interferon genes defines the critical region on 9p that is detected in lung cancers. Cancer Res 1993, 53, 2410-2415.
11. 11. Serrano M, Hannon GJ, Neach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993, 366, 704-707.
12. 12. Nobori T, Miura K, Wu DJ, Lois A, Takabayashi K, Carson DA. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 1994, 368, 753-756.
13. 13. Kamb A, Gruis NA, Weaver Feldhaus-J, et al. A cell cycle regulatory potentially involved in genesis of many tumor types. Science 1994, 264, 436-440.
14. 14. Igaki H, Sasaki H, Kishi T, et al. High frequent homozygous deletion of the p16 gene in esophageal cancer cell lines. Biochem Biophys Res Commun 1994, 203, 1090-1095.
15. 15. Caldas C, Hahn SA, et al. Frequent somatic mutations and homozygous deletions of the p16(MTS1) gene in pancreatic adenocarcinoma. Nat Genet 1994, 8, 27-32.
16. 16. Hayashi N, Sugimoto Y, Tsuchiya E, Ogawa M, Nakamura Y. Somatic mutations of the MTS (multiple tumor suppressor) 1/ CDK4I (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem Biophys Res Commun 1994, 202, 1426-1430.
17. 17. Sruck CH III, Gonzalez Z, Ulueta M, et al. p16 gene in uncultured tumors. Nature 1994, 370, 183-184.
18. 18. Cairns P, Mao L, Merlo A, et al. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 1994, 265, 415-417.
19. 19. Okamoto A, Demetrick DJ, Spillare EA, et al. Mutations and altered expression of p16INK4 in human cancer. Proc Natl Acad Sci USA 1994, 91, 11045-11049.
20. 20. Washimi O, Nagatake M, Osada H, et al. In vivo occurrence of p16(MTS1) and p15(MTS2) alterations preferentially in non-small cell lung cancers. Cancer Res 1995, 55, 514-517.
21. 21. Herman JG, Latif F, Weng Y, et al. Silencing of the VHL tumor suppressor gene by methylation in renal carcinoma. Proc Natl Acad Sci USA 1994, 91, 9700-9704.
22. 22. Merlo A, Herman JG, Mao L, et al. 5′CpG island methylation is associated with transcriptional silencing of the tumor suppressor p16/CDKN2 in human cancers. Nat Med 1995, 1, 686-692.
23. 23. Herman JG, Merlo A, Mao L, et al. Inactivation of the CDKN2/ p16/MTS1 is frequently associated with aberrant DNA methylation in all common human cancers. Cancer Res 1995, 55, 4525-4530.
24. INK4B1. Cancer Res 1996, 56, 722-727.
25. INK4A gene in liver cancer. Int J Cancer 1996, 67, 176-180.
26. INK4 in hepatocellular carcinoma. Hepatology 1996, 24, 575-579.
27. INK4b in undifferentiated mouse skin tumors. Cancer Res 1995, 55, 5168-5172.
28. INK4B/MTS2 in human leukemias and lymphomas. Cancer Res 1995, 55, 1436-1440.
29. 29. Sheu JC, Huang GT, Chou HC, Lee PH, Wang JT, Chen DS. Multiple hepatocellular carcinoma at the early stage have different clonality. Gastroenterology 1993, 105, 1471-1476.
30. 30. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res 1994, 54, 5547-5551.
31. 31. Li YJ, Hoang-Xuan K, Delattre JY, et al. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15(MTS2) and p16(MTS1) genes in gliomas. Oncogene 1995, 11, 59-600.